RLMD250117P1000
- 0.60
- 0.000.00%
Relmada Therapeutics Newsroom
Mizuho Securities Downgrades Relmada Therapeutics (RLMD) to a Hold
Jefferies Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $13
Relmada Therapeutics Analyst Ratings
Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
Analysts Offer Insights on Healthcare Companies: Relmada Therapeutics (RLMD) and Neumora Therapeutics, Inc. (NMRA)
Relmada Therapeutics Analyst Ratings
Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target
Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability
Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rallybio (RLYB), Avanos Medical (AVNS) and Relmada Therapeutics (RLMD)
Relmada Therapeutics: Advancements in MDD and MASLD Programs Bolster Buy Rating
Buy Rating for Relmada Therapeutics: Efficient Management, Promising Trials and Prudent Financial Control
Analysts Offer Insights on Healthcare Companies: AngioDynamics (ANGO), Enlivex (ENLV) and Relmada Therapeutics (RLMD)
Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) Gets a Buy From Mizuho Securities
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and Relmada Therapeutics (RLMD)
SVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)
Mizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
SVB Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)
SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating